Atlas Trials

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Clinical trial NCT07001384 · RECRUITING

Trial details

NCT number
NCT07001384
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma
Start date
2025-08-08
Primary completion
2031-08-08
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.